Assessing Opportunities & Demand Forecasting
Close to market, you’re likely to want to do detailed modelling of market scenarios. We can work on that with partners but our unique expertise lies in qualitative assessment of opportunities while therapeutics or vaccines are still in development.
This requires detailed understanding of the SRH environment and of the drivers and barriers which may exist in a fast-changing world.
What we’ve done
- A 28-country study on drivers and barriers to adoption of a preventative HIV vaccine for one of the world’s leading pharmaceutical companies. We did further in-depth research in 11 countries and a set of scenarios (in which we simulated interactions between stakeholders) in six countries. The countries included were upper income countries such as Canada and the UK; middle-income countries such as Brazil and; low-income countries such as Tanzania
- Forecasting the likely response across major European markets to possible adverse events from hormone replacement therapy, for a major pharmaceutical company
- A 27-country study on the drivers and barriers to adoption of effective treatment of hepatitis C in middle-income countries
- Assessing the likely market for partially-effective future vaccines in upper-, middle- and low-income countries for clients including Aeras (a non-profit biotech working in TB and with an interest in TB / HIV co-infection), the International AIDS Vaccine Initiative and two major multinational pharmaceutical companies